Cell and Gene Therapy, Industrial Impact

Preparing Biologics for Commercialization

December 14, 2022

Preparing Biologics
Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Spotlight

BioMotiv

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.

OTHER WHITEPAPERS
news image

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.

Read More
news image

Application of Single-Use Technologies(SUT) in Biosimilar Development

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.

Read More
news image

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

Read More
news image

Effective solutions for global challenges

whitePaper | April 24, 2023

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

Read More
news image

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Read More
news image

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

Read More

Spotlight

BioMotiv

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.

Events